Clinical Trials Logo

Clinical Trial Summary

Severe acute respiratory syndrome (SARS) is an emerging infectious disease caused by a novel coronavirus (SARS-CoV). The major clinical features of SARS include fever, dyspnea, lymphopenia, and a rapid progression of pulmonary infiltrates on chest radiologic images. The SARS-related deaths have resulted mainly from pulmonary complications, including progressive respiratory failure due to alveolar damage and acute respiratory distress syndrome (ARDS). Pathological changes in SARS suggest that SARS sequelae such as infiltration of PMN in lung tissue, multiple organ dysfunction and ARDS have been associated with cytokines and chemokine dysregulation. Some patients still manifested lung injury at a time when the viral load was falling also supports the immune nature of the lung damage. We therefore undertook an analysis of dynamic production of cytokine/chemokines in SARS patients with an initial normal chest radiograph in order to improve understanding of disease pathogenesis and improve patient management.


Clinical Trial Description

n/a


Study Design

Observational Model: Case Control, Time Perspective: Longitudinal


Related Conditions & MeSH terms


NCT number NCT00173459
Study type Observational
Source National Taiwan University Hospital
Contact
Status Completed
Phase N/A

See also
  Status Clinical Trial Phase
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Completed NCT04327479 - Characterization of Cardiovascular Diseases and Risk Factors in Patients With Suspected SARS-CoV2/Covid-19 Infection
Completed NCT00342524 - Collection of Convalescent SARS Plasma by Apheresis N/A
Recruiting NCT04306705 - Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19
Completed NCT04357860 - Clinical Trial of Sarilumab in Adults With COVID-19 Phase 2
Completed NCT04353674 - Modulation of Hyperinflammation in COVID-19 N/A
Withdrawn NCT01376765 - Phase I Dose Escalation SARS-CoV Recombinant S Protein, With and Without Adjuvant, Vaccine Study Phase 1